Viking Therapeutics has announced positive results from a Phase I clinical trial of VK2735, an oral medication for obesity.

FSD Pharma has announced the initiation of a Phase 1 clinical trial for a novel compound, Lucid-21-302, intended to treat multiple sclerosis (MS).

Cantargia a drug under investigation for use in treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Sagimet Biosciences a drug candidate aimed at treating metabolic dysfunction-associated steatohepatitis (MASH).

Iambic Therapeutics has dosed the first patient in a Phase 1 clinical trial for IAM1363.

This is a phase 1b/2a study that evaluates the safety and efficacy of Pexa-Vec, a modified vaccinia virus, when used alongside cemiplimab, an anti-PD-1 monoclonal antibody from Regeneron Pharmaceuticals Inc.

Immuneering Corporation, a clinical-stage oncology firm, has initiated a Phase 1/2a clinical trial for IMM-6-415, a novel Deep Cyclic Inhibitor (DCI) targeting the MAPK pathway.

AFM24 Clinical Trial Updates: In a Phase 1/2a study combining AFM24 with atezolizumab for non-small cell lung cancer (NSCLC) patients with EGFR-wildtype.

The preliminary safety findings from a Phase 1B clinical trial involving VRON-0200, a groundbreaking immunotherapy for chronic hepatitis B (HBV), were recently highlighted.

In a recent phase 1b clinical trial, patients received multiple injections of a novel immunotherapy, CAN-3110, developed by Candel Therapeutics.

MapLight Therapeutics has initiated a Phase 1 clinical trial for ML-007/PAC, a novel combination therapy aimed at treating schizophrenia and Alzheimer's disease psychosis.

Gilead Sciences, Inc. and Xilio Therapeutics, Inc. have announced an exclusive license agreement for the development and commercialization of Xilio's tumor-activated IL-12 program, XTX301.